NeuroSense Therapeutics (NASDAQ:NRSN) Stock Rating Lowered by Roth Capital

NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by Roth Capital from a “strong-buy” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other brokerages also recently commented on NRSN. HC Wainwright began coverage on shares of NeuroSense Therapeutics in a report on Thursday, September 3rd. They set a “buy” rating for the company. Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, NeuroSense Therapeutics presently has an average rating of “Hold” and a consensus target price of $170.00.

NeuroSense Therapeutics Price Performance

Shares of NRSN opened at $3.49 on Monday. The firm has a market capitalization of $6.63 million, a PE ratio of -0.32 and a beta of 1.66. The company’s 50-day moving average is $7.15 and its 200-day moving average is $12.11. NeuroSense Therapeutics has a fifty-two week low of $3.28 and a fifty-two week high of $26.64.

Institutional Trading of NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned 0.21% of NeuroSense Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is centered on therapeutic approaches intended to address multiple disease mechanisms, including neuroinflammation, abnormal RNA regulation and other biological processes associated with the progression of neurological disorders.

Its leading product candidate is PrimeC, an oral combination formulation of ciprofloxacin and celecoxib being developed primarily for amyotrophic lateral sclerosis (ALS).